NAV
$160.52
AUM
$8.4B
Expense Ratio
-
Dividend Yield
0.36%
Beta
1.12
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +32.02% | +25.11% | +24.98% | +92.60% | +24.86% | +3.41% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | TVTX | Travere Therapeutics Inc Ordinary Shares | 1.79% |
| 2 | RVMD | Revolution Medicines Inc Ordinary Shares | 1.78% |
| 3 | ALKS | Alkermes PLC | 1.71% |
| 4 | TWST | Twist Bioscience Corp | 1.60% |
| 5 | TGTX | TG Therapeutics Inc | 1.52% |
| 6 | ARWR | Arrowhead Pharmaceuticals Inc | 1.51% |
| 7 | BEAM | Beam Therapeutics Inc | 1.42% |
| 8 | NBIX | Neurocrine Biosciences Inc | 1.37% |
| 9 | KRYS | Krystal Biotech Inc | 1.36% |
| 10 | EXEL | Exelixis Inc | 1.36% |
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
Inception Date: 2006-01-31